Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2026
Regulators often diverge from FDA on expedited oncology approvals
22 June 2026 - Among oncology drugs first approved by the US FDA, other regulatory authorities varied in how they ...
Posted by Michael Wonder on 03 Jun 2026
FDA approves more orphan drugs with specific cancer, paediatric indications over EMA
2 June 2026 - The US FDA is more likely to approve drugs with an orphan designation that were indicated ...
Posted by Michael Wonder on 27 May 2026
Outlook Therapeutics wins appeal following formal dispute resolution process for ONS-5010/Lytenava (bevacizumab-vikg) company plans to resubmit BLA to the FDA in June 2026
26 May 2026 - Outlook Therapeutics today announced that the US FDA has granted the appeal following completion of the ...
Posted by Michael Wonder on 20 May 2026
FDA official offers examples of RWE being used to secure drug approval
19 May 2026 - An official from the US FDA on Monday presented three case studies demonstrating how sponsors effectively ...
Posted by Michael Wonder on 12 May 2026
FDA advances drug repurposing to address unmet medical needs
11 May 2026 - Agency is particularly focused on new uses to treat chronic or rare diseases. ...
Posted by Michael Wonder on 03 May 2026
US pushes real time clinical trials to eliminate “dead time” in approvals
1 May 2026 - The US FDA is testing “real time clinical trials,” which it says will provide faster access ...
Posted by Michael Wonder on 29 Apr 2026
FDA announces major steps to implement real time clinical trials
28 April 2026 - The US FDA today announced two major steps as part of an initiative to advance the implementation ...
Posted by Michael Wonder on 23 Apr 2026
CMS and FDA announce RAPID coverage pathway to accelerate patient access to life changing medical devices
23 April 2026 - New pathway cuts red tape and brings predictability to Medicare coverage for Breakthrough Devices. ...
Posted by Michael Wonder on 21 Apr 2026
20 years of priority review vouchers, a tool for spurring needed drugs
19 April 2026 - Occasionally I’ll go watch a TV show taping. Big-name shows are sold out, with long lines ...
Posted by Michael Wonder on 21 Mar 2026
Toward greater transparency at the FDA - now is the time to act
18 March 2026 - The US FDA has generally sought to uphold the highest standards of scientific rigour in its regulation ...
Posted by Michael Wonder on 20 Mar 2026
Political influence ‘a serious problem’ for FDA under Trump, former commissioner says
19 March 2026 - Political influence ‘a serious problem’ for FDA under Trump, former commissioner says. ...
Posted by Michael Wonder on 09 Mar 2026
FDA takes further steps to streamline biosimilar development and make medicines more affordable
9 March 2026 - The US FDA today announced another major step in its initiative to streamline the development of biosimilar ...
Posted by Michael Wonder on 28 Feb 2026
Opus Genetics announces FDA acceptance of supplemental new drug application for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia
25 February 2026 - Opus Genetics today announced that the US FDA has accepted for review the supplemental new drug ...
Posted by Michael Wonder on 20 Feb 2026
One pivotal trial, the new default option for FDA approval — ending the two-trial dogma
18 February 2026 - This Sounding Board announces a new FDA policy that the default requirement for FDA approvals will be ...
Posted by Michael Wonder on 18 Feb 2026
Moderna announces the US FDA will initiate the review of its investigational seasonal influenza vaccine submission
18 February 2026 - Moderna has received a PDUFA goal date of 5 August 2026. ...